SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 2, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United...

- Third quarter Orenitram® net revenue growth of 20% and Tyvaso® net revenue growth of 17% year-over-year - Remodulin® sequential quarterly net revenue growth of 5% - INCREASE sNDA under FDA review with April...

Clinical study data suggests Tyvaso® improved forced vital capacity, an important measure of lung function, in patients with pulmonary hypertension associated with interstitial lung disease Seven poster presentations...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2020 financial results before the...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present clinical trial data on Tyvaso® (treprostinil) Inhalation...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 16, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the appointment of Linda Maxwell, M.D. to its Board of Directors as an...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 17, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for review the...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 5, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United...

- Second quarter Orenitram® revenue growth of 40% year-over-year- INCREASE sNDA submitted to FDA SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 29, 2020 /PRNewswire/ -- United Therapeutics...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 23, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the United States Patent and Trademark Office issued a new patent on July...